Review
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Nov 27, 2024; 16(11): 1225-1242
Published online Nov 27, 2024. doi: 10.4254/wjh.v16.i11.1225
Autoimmune hepatitis: Towards a personalized treatment
Alejandro Costaguta, Guillermo Costaguta, Fernando Álvarez
Alejandro Costaguta, Department of Hepatology and Liver Transplant Unit, Sanatorio de Niños de Rosario, Rosario 2000, Santa Fe, Argentina
Guillermo Costaguta, Department of Gastroenterology, Hepatology, and Nutrition, CHU Sainte-Justine, Montreal H3T 1C5, Quebec, Canada
Fernando Álvarez, Department of Pediatrics, CHU Sainte-Justine, Montreal H3T 1C5, Quebec, Canada
Co-first authors: Alejandro Costaguta and Guillermo Costaguta.
Author contributions: Costaguta A contributed to the conception of the work, data collection and review, critical revision of the final draft, and approval for publication; Costaguta G contributed to conception of the work, collection of data, draft of the first version, and approval for publication; Álvarez F contributed to data collection, critical review of the final draft, and approval for publication.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Alejandro Costaguta, MD, Chief Physician, Doctor, Staff Physician, Department of Hepatology and Liver Transplant Unit, Sanatorio de Niños de Rosario, Alvear 863, CP 2000, Rosario 2000, Santa Fe, Argentina. alejandro.costaguta@gmail.com
Received: June 25, 2024
Revised: September 2, 2024
Accepted: October 11, 2024
Published online: November 27, 2024
Processing time: 133 Days and 10.3 Hours
Core Tip

Core Tip: Autoimmune hepatitis is a serious condition that affects both adults and children and has a poor prognosis if left untreated. Historically, treatment has involved high-dose steroids to induce remission and maintenance therapy with azathioprine, which achieves remission in 80% of cases but requires alternative therapies for the remaining 20%. While there have been advancements in immunosuppressive therapies for other diseases, treatment protocols for autoimmune hepatitis have remained largely unchanged. In this article, we explored alternative treatment options for patients for whom the standard protocol is not suitable.